Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
The annual congress of the European Society for Medical Oncology took place between the 19th and the 23rd October. At the meeting, Boehringer Ingelheim hosted a symposium and presented a number of publications highlighting our advances in the treatment of cancer.
At this symposium, an international faculty of experts discussed treatment sequencing in EGFR mutation-positive NSCLC, the efficacy of EGFR TKIs in patients with uncommon mutations, and treatment considerations for second-line and beyond in non-mutated, non-squamous NSCLC.
Please see below where you can access materials from our symposium.
We also presented a number of publications during the scientific program at ESMO – please see downloadable versions below.
Find out more about other oncology events
Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.
*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: October 2018
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue